We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Information for prospective growers of low THC cannabis (industrial hemp), for the production of seed and fibre only.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
How offender healthcare is managed in prisons and in the community.
In October 2001 the Home Secretary asked the Advisory Council on the Misuse of Drugs to review the classification of cannabis preparations in…
How to use a cost benefit analysis to evaluate your digital health product.
Advice for medical professionals to follow when assessing drivers with drug or alcohol misuse or dependence.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
Following the Home Secretary’s request in March 2005, the Advisory Council has reviewed its position on the classification of cannabis products…
How to use a patient-reported outcomes and experiences study to evaluate your digital health product.
What you need to know before you can place a medical device on the Great Britain market with a UKCA mark.
How investigators and sponsors should manage clinical trials during COVID-19
Data on the real-world efficacy of the COVID-19 vaccines.
Guidance for commissioners and health professionals to make decisions about mental health services and interventions based on data and analysis.
How to use a cost consequence analysis to evaluate your digital health product.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
This edition of Health Matters focuses on smoking among people living with a broad range of mental health conditions.
Information relating to the Tobacco and Vapes Bill which was introduced in the House of Commons on 20 March 2024.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).